Bio Spec Overview
Ignite Creation Date:
2025-12-25 @ 12:13 AM
Last Modification Date:
2025-12-25 @ 12:13 AM
Retention:
SAMPLES_WITHOUT_DNA
Description:
Prospective analysis of biological material from samples of peripheral blood (PB) of patients with high risk prostate cancer treated with dose escalation RT combined with androgen deprivation (AD)
The sampling of PB for detection of CTCs was performed at 4 timepoints:
* Before starting any treatment
* Prior to the start of RT and after neoadjuvant AD
* At the end of RT (1-3 months)
* 6-12 months following the end of RT in patients with 0 CTCs in the 1º determination and positive CTCs in the 2º or 3º determination.
A cut off of 0 vs ≥ 1 CTC/7.5 mL blood was defined as a threshold for negative versus positive CTCs status.
The sampling of PB for detection of CTCs was performed at 4 timepoints:
* Before starting any treatment
* Prior to the start of RT and after neoadjuvant AD
* At the end of RT (1-3 months)
* 6-12 months following the end of RT in patients with 0 CTCs in the 1º determination and positive CTCs in the 2º or 3º determination.
A cut off of 0 vs ≥ 1 CTC/7.5 mL blood was defined as a threshold for negative versus positive CTCs status.
Section:
Prospective analysis of biological material from samples of peripheral blood (PB) of patients with high risk prostate cancer treated with dose escalation RT combined with androgen deprivation (AD)
The sampling of PB for detection of CTCs was performed at 4 timepoints:
* Before starting any treatment
* Prior to the start of RT and after neoadjuvant AD
* At the end of RT (1-3 months)
* 6-12 months following the end of RT in patients with 0 CTCs in the 1º determination and positive CTCs in the 2º or 3º determination.
A cut off of 0 vs ≥ 1 CTC/7.5 mL blood was defined as a threshold for negative versus positive CTCs status.